tweetindex
IT

gilberto lopes ✓

@GlopesMd · Miami, FL · joined 16 Nov 2013

Chief MedOnc @SylvesterCancer @UnivMiami. Improving access to cancer meds in LMICs. Editor-in-Chief emeritus JCO GO, Board Member @UICC - chair #ATOMcoalition

37 564Followers
40 000Following
57 608Posts total
10.7KViews on collected posts

Ultimi post

Visual summary of today’s phase 3 DeLLphi-305 update in ES-SCLC: tarlatamab + durvalumab maintenance improved OS vs durvalumab alone after induction durvalumab + platinum/etoposide. PFS and ORR also positive. Full data still needed. #SCLC #LCSM https://t.co/pyeQbPyoRc
SCLC update: DeLLphi-305 tarlatamab plus durvalumab improved overall survival
Key findings: overall survival improved, PFS and ORR also positive
Why it matters: moving DLL3-directed therapy earlier in ES-SCLC
What we still need: hazard ratio, median overall survival, subgroup results, and detailed safety
1K views · 15 likes · 7 reposts · 1 replies Open on X →
1/3 Big news in #SCLC today. Phase III DeLLphi-305: tarlatamab + durvalumab maintenance improved OS vs durvalumab alone after first-line platinum/etoposide + durvalumab in ES-SCLC. PFS and ORR also positive. Very encouraging—full data will matter. 1K views · 13 likes · 3 reposts · 2 replies Open on X →
@iaslc #WCLC26 @oncoalert @oncodaily @larvol @tribeMDUS @sylvestercancer @oncbrothers @chinmay @Jani_Chinmay @latinamd @colazagasti @openmedicineHQ @asco @myesmo @openmedkate @openmedben @chadinabhan 760 views · 6 likes · 2 reposts · 0 replies Open on X →
Seoul, Rebuilt: What a City and the World Conference on Lung Cancer Can Teach Us About Progress https://t.co/b6TNHeXEOV @IASLC #WCLC26 @uicc 1.8K views · 19 likes · 6 reposts · 1 replies Open on X →
@GlopesMd @WSJopinion Really nice piece my friend 👌🏻👍🏻 31 views · 1 likes · 0 reposts · 0 replies Open on X →
@GlopesMd @WSJopinion well said 172 views · 1 likes · 1 reposts · 1 replies Open on X →
“Americans grew richer in the goods that markets could freely supply, and poorer in the three purchases that define middle-class standing: a house, a degree and a doctor.” 2.5K views · 7 likes · 3 reposts · 0 replies Open on X →
My piece @WSJopinion: Americans Got Wealthier but Don’t Feel Like It https://t.co/QiKHd2XY1Y https://t.co/HZNwsDLl8y
3.4K views · 8 likes · 3 reposts · 2 replies Open on X →

Rispetto ad account della stessa dimensione

8 post degli ultimi 90 giorni, accanto alla fascia di 10K–100K follower. esattamente sulla mediana della sua fascia di follower.

Visualizzazioni mediane1 025questo account924mediana per 10K–100K
Copertura, %2.73%questo account3.62%mediana per 10K–100K
Interazione, %1.63%questo account1.52%mediana per 10K–100K
MetricaQuesto accountMediana per 10K–100KRapporto
Visualizzazioni mediane per post1 0259241.11×
Copertura (visualizzazioni ÷ follower)2.73%3.62%0.75×
Tasso di interazione1.63%1.52%1.07×

Altri account di questa fascia →   Confronta con un altro account →   Come sono costruiti questi parametri →

Growth & engagement

How the posts we collected actually performed: views and reaction rate post by post, what the audience did with them, and where the follower count goes.

Views per post

3.4K5 Aug
2.5K6 Aug
172
3120 Aug
1.8K8 Sep
760
1K
1K

Last 8 collected posts, oldest on the left. The scale is logarithmic: one post can outrun the rest a hundred times over.

Engagement rate per post

0.41%5 Aug
0.41%6 Aug
1.74%
3.23%20 Aug
1.51%8 Sep
1.05%
1.77%
2.22%

Reactions — likes, reposts, replies and quotes — divided by views. Median for 10K–100K accounts is 1.52%.

What the audience does

Likes63.1%70 in total
Reposts22.5%25 in total
Replies6.3%7 in total
Quotes1.8%2 in total
Bookmarks6.3%7 in total

Share of every reaction we collected for this account. Replies mean argument, reposts mean endorsement, bookmarks mean the post was worth keeping.

The follower curve appears once this account has two daily snapshots — we take one a day, and this one is on its first.

Account simili